About Conference

The 3rd International Conference on World Heart Care will take place on August 11-12, 2025, in Toronto, Canada. This premier gathering for healthcare professionals, researchers, and innovators in the field of cardiovascular medicine aims to provide an unparalleled platform for discussing the latest advancements, research, and trends in heart health. Attendees will have the opportunity to engage with experts, share insights, and explore groundbreaking solutions to address the global cardiovascular disease burden.

World Heart 2025 will feature a diverse range of sessions, including keynote presentations, panel discussions, and interactive workshops, covering key topics such as cardiovascular prevention, innovative treatment options, cardiovascular imaging, and the latest research on heart disease mechanisms. With a focus on collaboration, the event will bring together leading cardiologists, clinicians, researchers, and industry experts to share knowledge and foster partnerships that drive progress in heart care. Whether you're a healthcare provider, researcher, or policymaker, World Heart 2025 will offer valuable insights into the evolving landscape of cardiovascular health and provide opportunities to contribute to shaping the future of heart disease prevention and treatment.

Target Audience:

• Cardiologists
• Professors, Associate Professors
• Heart Societies & Associations
• Cardio-thoracic Surgeons
• Cardiac Surgeons
• Research Scholars
• Cardiology Fellows
• Research Institutes
• Vascular Biologists
• Manufacturing
• Associations and Societies of Cardiology
• Training Institutes
• Cardiology Students, Scientists
• Cardiology and Cardiac Nursing Associations
• Graduates and Post Graduates
• Directors, CEO’s of Organizations
• Medicine Experts

Sessions and Tracks

Track 01:  Advances in Cardiovascular Medicine

Cardiovascular medicine is a rapidly advancing field focused on the prevention, diagnosis, and treatment of heart and vascular diseases. Recent innovations, such as personalized medicine, have revolutionized treatment by tailoring therapies based on an individual’s genetic makeup and lifestyle. Advanced diagnostic tools, including high-resolution imaging techniques and high-sensitivity biomarkers, have enabled early detection of cardiovascular conditions, sometimes even before symptoms appear. Novel pharmacological agents, including biologics and gene therapies, have greatly enhanced the management of conditions like heart failure, arrhythmias, and coronary artery disease. Minimally invasive procedures such as transcatheter aortic valve replacement have improved surgical outcomes by reducing recovery times and improving prognosis. Digital health tools, including wearable and mobile apps, are increasingly used to monitor cardiovascular health, providing continuous data that allows for early intervention and more personalized care. Technological breakthroughs continue to improve treatment options in cardiovascular care. The use of digital health tools and telemedicine has also gained significant attention, as they enable real-time monitoring of heart health and the ability to intervene quickly in case of abnormalities. These advancements are continuously reshaping the landscape of cardiovascular medicine, promising a future where heart disease can be prevented, detected, and treated with unprecedented precision.

Track 02:  Cardiovascular Imaging and Diagnostics

Cardiovascular imaging has seen remarkable advancements, making it an indispensable tool in diagnosing and managing heart diseases. Technologies like echocardiography, magnetic resonance imaging, and computed tomography have improved the ability to assess heart structure, function, and blood flow, providing detailed insights that are critical for diagnosis and treatment planning. With 3D imaging and real-time guidance during interventions, these tools enable more accurate procedures and better surgical outcomes. Molecular imaging, such as positron emission tomography, is particularly useful in detecting early cellular changes in cardiovascular tissues, providing additional insights that are crucial for early diagnosis and personalized care. Advancements in diagnostic biomarkers complement imaging techniques, offering a more comprehensive understanding of cardiovascular health. One of the most promising areas in cardiovascular imaging is the integration of artificial intelligence. AI algorithms are being used to enhance the interpretation of complex medical images, leading to faster, more accurate diagnoses and more tailored treatment plans. These innovations are making cardiovascular diagnostics faster, less invasive, and more reliable, allowing healthcare providers to deliver more personalized and timely treatment.

Track 03:  Heart Failure Management

Heart failure is a complex condition where the heart cannot pump blood effectively, and its management has made significant strides in recent years. Pharmacological treatments such as ACE inhibitors, beta-blockers, and newer agents like SGLT2 inhibitors and angiotensin receptor-neprilysin inhibitors have dramatically improved patient outcomes, reducing hospitalizations and enhancing quality of life. These medications help manage symptoms, prevent progression, and reduce the burden of disease on the heart. In addition to drugs, the use of implantable devices, including left ventricular assist devices and wearable defibrillators, has greatly advanced heart failure management, especially for patients with severe forms of the disease. These devices provide critical support to the heart, improving survival rates and providing patients with greater independence. Innovations in heart failure care also include personalized medicine, where genetic profiling helps guide treatment choices, ensuring optimal therapy for individual patients. Advanced heart failure management has become a multidisciplinary approach, involving cardiologists, nurses, and rehabilitation specialists to ensure the best possible outcomes. As new therapies continue to emerge, including regenerative treatments and cell-based therapies, the future of heart failure management looks promising, with the potential for better quality of life and longer survival for patients.

Track 04:  Arrhythmias and Electrophysiology

Arrhythmias are a group of disorders in which the heart’s rhythm is abnormal, potentially leading to serious complications such as stroke, heart failure, or sudden cardiac death. The use of electrophysiological mapping and catheter-based ablation, which allow clinicians to precisely locate and treat abnormal electrical pathways in the heart. Radiofrequency and cryoablation techniques, which have become the gold standard for treating arrhythmias like atrial fibrillation, will be explored. The integration of new technologies, such as machine learning algorithms and advanced mapping systems, is also revolutionizing the diagnosis and treatment of arrhythmias. These developments promise to improve patient outcomes by providing more accurate, personalized care. Advances in genetic research and molecular profiling are providing deeper insights into the underlying causes of arrhythmias, paving the way for novel therapies that target the genetic and molecular drivers of these disorders. Genetic testing and molecular profiling are shedding light on the hereditary factors underlying arrhythmias, leading to targeted therapies for individuals at higher genetic risk. New approaches, such as gene editing techniques, are being explored to correct genetic mutations that cause arrhythmias, potentially providing a permanent cure.

Track 05:  Preventive Cardiology and Lifestyle Medicine

Preventive cardiology aims to reduce the incidence of cardiovascular diseases by addressing risk factors early and promoting healthy lifestyle choices. Key interventions include managing conditions like hypertension, diabetes, and hyperlipidemia, along with promoting smoking cessation, physical activity, and healthy eating. Recent developments in the field have focused on integrating personalized medicine into prevention, where genetic testing and advanced biomarkers help identify individuals at high risk for cardiovascular diseases before symptoms occur. Lifestyle medicine plays a critical role in the prevention of cardiovascular diseases, with research showing that changes in diet, exercise, and stress management can significantly reduce the risk of heart disease. As the field of preventive cardiology continues to evolve, there is a growing emphasis on a holistic approach to heart health, where medical interventions and lifestyle changes are integrated to provide comprehensive care for individuals at risk of cardiovascular disease. Novel treatments aimed at reversing endothelial dysfunction, improving lipid metabolism, and managing inflammation are becoming key components of cardiovascular disease prevention. Future innovations will likely see personalized preventive strategies that integrate digital health tools for ongoing monitoring and adjustment of lifestyle factors, enabling patients to maintain optimal heart health proactively.

Track 06:  Pediatric Cardiology

Pediatric cardiology focuses on the diagnosis, treatment, and management of heart conditions in children, from congenital defects to acquired diseases. Recent advancements in pediatric cardiology have significantly improved outcomes for children with heart conditions, particularly those with congenital heart defects. These conditions, which affect the heart structure and function from birth, are now identified earlier thanks to improved screening methods such as fetal echocardiography and genetic testing. With early detection, treatments can begin sooner, leading to better management and long-term outcomes. Surgical interventions, such as open-heart surgery and catheter-based procedures, have also seen tremendous improvements, with less invasive techniques now available for many conditions, significantly reducing recovery times and enhancing the quality of life for affected children. New approaches in post-operative care, including multidisciplinary teams and rehabilitation programs, have also contributed to improved survival rates and functional recovery. In cases requiring surgery, innovations in post-operative care, including enhanced recovery protocols and the use of 3D-printed models for surgical planning, have improved recovery times and reduced complications. With growing attention to the emotional and psychological needs of children with heart conditions, multidisciplinary teams that include pediatric cardiologists, surgeons, nurses, and psychologists are providing holistic care to support the child and their family throughout the treatment journey.

Track 07:  Cardiovascular Surgery and Interventions

Cardiovascular Surgery and Interventions focus on the latest developments in cardiovascular surgery, including robotic-assisted surgery and new approaches for coronary artery bypass grafting, valve repair, and aortic surgery. Minimally invasive surgeries, such as percutaneous coronary interventions and transcatheter aortic valve replacement, have revolutionized the way heart conditions are treated, offering patients faster recovery times, reduced hospital stays, and lower complication rates. Innovations in surgical tools, including 3D-printed models for preoperative planning and robotic-assisted techniques, are improving the precision of cardiovascular surgeries. The role of multidisciplinary teams in delivering comprehensive care, from diagnosis through rehabilitation, will also be emphasized, collaboration between surgeons, cardiologists, anesthesiologists, and rehabilitation specialists is improving patient outcomes. Minimally invasive techniques, like percutaneous coronary interventions and transcatheter aortic valve replacement, have revolutionized the treatment of aortic stenosis and coronary artery disease, offering a less traumatic option than traditional open surgeries. Multidisciplinary care teams are now an integral part of the surgical process, ensuring comprehensive care before, during, and after surgery, which improves overall patient outcomes and reduces the risk of complications.

Track 08:  Cardiovascular Pharmacology and Drug Development

Cardiovascular Pharmacology and Drug Development focus on the latest advancements in cardiovascular pharmacology, particularly the development of new drug classes aimed at treating various heart conditions. New therapies for hypertension, hyperlipidemia, and heart failure, including SGLT2 inhibitors, PCSK9 inhibitors, and angiotensin receptor-neprilysin inhibitors will be discussed in detail. These treatments are revolutionizing the management of cardiovascular diseases by targeting the underlying mechanisms that cause heart disease, offering new hope for patients who have not responded to conventional therapies. Novel drug delivery systems, including nanoparticles and biologics, are also making their way into cardiovascular treatment regimens, enabling more targeted and efficient drug delivery. Challenges in cardiovascular drug development, including regulatory hurdles and safety concerns, will be addressed, with a focus on overcoming these barriers to accelerate the availability of new therapies. The field is also seeing an increasing focus on regenerative medicine, where drugs aimed at stimulating heart tissue repair and regeneration offer the potential to reverse the damage caused by heart disease. Challenges in cardiovascular drug development, such as the need for long-term safety data, cost, and regulatory approval, remain, but ongoing advancements in biotechnology and clinical research offer hope for more effective treatments in the future.

Track 09:  Cardio-Oncology

Cardio-oncology is an emerging field that focuses on the cardiovascular health of cancer patients and survivors, addressing the intersection of cancer therapies and heart disease. Cardio-Oncology explore the impact of chemotherapy, radiation, and novel targeted therapies on the cardiovascular system, which can lead to a variety of cardiac issues, including heart failure, arrhythmias, and vascular damage. Advances in understanding the mechanisms by which cancer treatments affect the heart are improving early detection and management of these conditions. New strategies in cardio-oncology, such as the use of heart-protective medications and lifestyle interventions, are becoming vital in preventing long-term cardiovascular complications. As cancer survival rates continue to rise, a more comprehensive approach that addresses both oncological and cardiovascular health is becoming essential. Strategies such as the use of ACE inhibitors, beta-blockers, and newer agents like dexrazoxane are helping protect the heart from the toxic effects of chemotherapy. Advances in early detection, including biomarkers and imaging, enable cardiologists to monitor and treat cardiac issues early, preventing long-term cardiovascular complications in cancer survivors. A comprehensive approach that includes both oncological and cardiovascular specialists is crucial for managing the long-term health of cancer patients.

Track 10:  Hypertension and Cardiovascular Risk Management

Hypertension, often referred to as the silent killer, is one of the primary risk factors for cardiovascular disease. New classes of antihypertensive medications, such as aldosterone antagonists, calcium channel blockers, and dual-renin-angiotensin-aldosterone system inhibitors, have shown promising results in controlling blood pressure and reducing cardiovascular events. Advances in blood pressure monitoring technologies, including wearable devices and home blood pressure monitoring, have made it easier for patients and healthcare providers to track and control hypertension outside of the clinical setting. It also explore the relationship between hypertension and other cardiovascular risk factors, such as diabetes and hyperlipidemia, and the importance of managing these comorbidities in tandem. Public health approaches to hypertension control, both at the individual and population levels, will be a key area of focus, with a particular emphasis on reducing the global burden of high blood pressure. Public health campaigns aimed at reducing salt intake, promoting physical activity, and improving dietary habits are also playing an essential role in the global effort to control hypertension and reduce its impact on cardiovascular health. 

Track 11:  Cardio-Metabolic Disorders

Cardio-metabolic disorders, which include conditions such as obesity, diabetes, metabolic syndrome, and dyslipidemia, have become some of the most significant risk factors for cardiovascular disease. Cardio-Metabolic Disorders  mainly focus on the pathophysiology of these interconnected conditions and their contribution to cardiovascular risk. Innovative treatments for these disorders, including GLP-1 receptor agonists, SGLT2 inhibitors, and newer lipid-lowering therapies like PCSK9 inhibitors, will be highlighted. The impact of bariatric surgery in reversing some of the underlying metabolic disturbances and improving cardiovascular outcomes will also be discussed. The role of early screening for metabolic risk factors, including regular blood glucose and lipid level assessments, will also be emphasized. As the global prevalence of obesity and metabolic disorders continues to rise, an integrated approach to managing these conditions is crucial in reducing the burden of cardiovascular disease worldwide. The role of early screening for metabolic risk factors, including regular blood glucose and lipid level assessments, will be emphasized. As the global prevalence of obesity and metabolic disorders continues to rise, an integrated approach to managing these conditions is crucial in reducing the burden of cardiovascular disease worldwide.

Track 12:  Women’s Cardiovascular Health

Women’s cardiovascular health has gained increasing attention in recent years due to the unique risk factors and presentation of heart disease in women. Women’s Cardiovascular Health focus on the gender-specific aspects of cardiovascular disease, including hormonal influences, pregnancy-related complications such as preeclampsia and gestational diabetes, and the impact of menopause on cardiovascular risk. Women’s cardiovascular health has gained increasing attention in recent years due to the unique risk factors and presentation of heart disease in women. Recent advances in cardiovascular research have emphasized the need for sex-specific guidelines in the prevention, diagnosis, and treatment of heart disease. Impact of lifestyle factors such as smoking, diet, and physical activity will be explored, with a focus on how women can mitigate their cardiovascular risk through targeted interventions. As cardiovascular disease continues to be the leading cause of death among women, personalized care strategies that address the unique needs of women will be emphasized as a critical focus for future healthcare initiatives. As cardiovascular disease continues to be the leading cause of death among women, personalized care strategies addressing the unique needs of women will be emphasized as a critical focus for future healthcare initiatives.

Track 13:  Cardiac Rehabilitation and Recovery

Cardiac rehabilitation serves as a cornerstone in the recovery journey for individuals who have endured cardiovascular events like heart attacks or undergone procedures such as coronary artery bypass surgery. Psychological support, encompassing counseling and stress management, will also be explored as vital in addressing emotional challenges, such as anxiety and depression, which are commonly associated with cardiovascular disease. Emerging technologies are revolutionizing rehabilitation by integrating remote monitoring tools, telehealth platforms, and mobile health apps, making programs more accessible, particularly for patients in rural or underserved areas. These technologies enable real-time feedback, allowing healthcare providers to track progress and tailor interventions to individual needs. As cardiovascular disease continues to rise globally, the session will stress the urgency of expanding access to effective and scalable rehabilitation programs to reduce healthcare costs, improve survival rates, and enhance the overall quality of life for patients. By bridging the gap between technology and personalized care, cardiac rehabilitation programs are poised to redefine recovery and long-term cardiovascular health.

Track 14:  Nanotechnology in Cardiovascular Medicine

Nanotechnology is revolutionizing the field of cardiovascular medicine by offering novel ways to diagnose, treat, and prevent heart disease. Nanoparticles can be engineered to deliver drugs directly to targeted areas of the cardiovascular system, allowing for more precise treatments with fewer side effects. Nanotechnology-based imaging agents are improving the sensitivity and specificity of cardiovascular diagnostics, enabling earlier detection of heart disease at the molecular level. Challenges in the clinical application of nanotechnology, including regulatory issues, biocompatibility, and safety concerns addressed. Nanotechnology include nanoparticle-based drug delivery systems that target specific heart tissues with high precision, minimizing side effects and improving therapeutic outcomes. Nanoparticle will explore the challenges and ethical considerations associated with integrating nanotechnology into clinical practice, ensuring that safety and efficacy are prioritized. Insights into ongoing clinical trials and future applications of nanomaterials in cardiovascular interventions will provide attendees with a comprehensive understanding of the transformative potential of nanotechnology.

Track 15:  Artificial Intelligence in Cardiology

Artificial Intelligence is revolutionizing cardiology by advancing diagnostics, treatment strategies, and patient care. AI systems excel in identifying subtle markers and patterns within vast datasets, enabling early and precise diagnosis of conditions like coronary artery disease, heart failure, and arrhythmias. These technologies have proven particularly impactful in imaging modalities, including echocardiography and cardiac MRI, where they provide high-speed, highly accurate analysis, significantly enhancing diagnostic precision. Beyond diagnostics, AI is driving the shift towards personalized medicine by integrating genetic information, lifestyle data, and clinical histories to create customized treatment plans. This personalized approach ensures patients receive optimized therapies with minimized risks of adverse effects, ultimately improving outcomes. AI is also transforming hospital workflows by predicting patient outcomes, efficiently managing resources, and guiding robotic-assisted cardiovascular surgeries. These innovations streamline processes, reduce delays, and make cutting-edge care more accessible, even in resource-limited settings. However, as the adoption of AI grows, it introduces significant challenges, such as ensuring data privacy, addressing algorithmic biases, and maintaining ethical transparency in clinical applications.

Track 16:  Cardiac Transplantation and Mechanical Circulatory Support

Cardiac transplantation and mechanical circulatory support are essential treatment options for patients with end-stage heart failure. It focus on the latest advancements in heart transplantation, including donor organ allocation, organ preservation techniques, and strategies to improve transplant outcomes. These devices have evolved significantly, with newer, more efficient models providing improved quality of life and survival rates. Cardiac Transplantation advances in MCS technology, including miniaturization, patient-specific customization, and the integration of wireless monitoring systems to track device performance. As the field of cardiac transplantation and MCS continues to evolve, emphasize the need for a multidisciplinary approach that includes cardiologists, transplant surgeons, nurses, and rehabilitation specialists to ensure optimal patient outcomes.. The management of complications post-transplant, including rejection, immunosuppressive therapy, and long-term patient monitoring, will also be covered. Insights into improving patient outcomes and extending the longevity of transplanted organs will be shared through case studies and clinical trials.

Track 17:  Genetics and Precision Medicine in Cardiology

Precision medicine has revolutionized the treatment of cardiovascular diseases by enabling a more personalized approach to patient care based on genetic profiles. Personalized medicine in cardiology is facilitating the development of targeted therapies that address specific molecular pathways involved in cardiovascular conditions. Precision medicine has revolutionized cardiovascular care by enabling personalized treatments based on genetic profiles. These advances have led to the emergence of novel drug classes, including those aimed at treating familial hypercholesterolemia and other genetically linked heart diseases. With the integration of big data and bioinformatics, clinicians can now analyze vast genetic and clinical datasets to better understand the underlying mechanisms of cardiovascular diseases, further enhancing precision treatment. Genetic counseling's role in educating families about inherited risks and ensuring appropriate surveillance and management strategies will also be discussed. Genetics and Precision Medicine emphasize the need for collaboration between geneticists, cardiologists, and healthcare providers to ensure that precision medicine becomes a standard practice in cardiovascular care.

Track 18:  Vascular Biology and Hypertension

Vascular biology and hypertension are at the core of cardiovascular health, with endothelial dysfunction and vascular aging playing pivotal roles in the onset and progression of hypertension and other cardiovascular diseases. Cutting-edge therapies aimed at restoring endothelial function and improving vascular tone will be discussed, including the use of nitric oxide donors, endothelial progenitor cell therapies, and novel pharmacological agents that target the vascular endothelium. Experts will present the latest findings in vascular biology research, exploring how these discoveries can lead to more effective treatments for hypertension and its complications. A multidisciplinary approach involving cardiologists, pharmacologists, dietitians, and exercise physiologists will be emphasized to ensure comprehensive care for patients with vascular diseases.  Attendees will learn about novel biomarkers for assessing vascular health and the emerging therapies designed to target these biomarkers in the management of vascular diseases such as peripheral arterial disease. The role of lifestyle interventions, including diet, exercise, and stress management, in improving vascular health will also be explored. Experts will discuss the evolving landscape of vascular biology research and its potential to lead to innovative therapies for hypertension and other vascular-related diseases.

Track 19:  Cardiovascular Nutrition and Dietetics

Nutrition plays a pivotal role in the prevention, management, and treatment of cardiovascular diseases, with growing evidence highlighting the significant impact of diet on heart health. Personalized nutrition is another core theme, with discussions on how genetic, environmental, and lifestyle factors can influence an individual's response to different diets. Cardiovascular Nutrition and Dietetics will explore the use of personalized dietary plans to optimize heart health based on individual risk profiles, taking into account factors like lipid levels, blood pressure, and family history of cardiovascular disease. The integration of nutrition experts into cardiology care teams will be a key discussion point, emphasizing how dietitians, in collaboration with cardiologists, can provide tailored nutrition counseling to improve patient outcomes and enhance adherence to dietary interventions. Practical strategies for overcoming barriers to healthy eating will be shared, with a focus on addressing common challenges such as lack of access to healthy foods, cultural dietary preferences, and long-term adherence. Cardiovascular Nutrition explore the broader public health implications of nutrition in cardiovascular disease prevention, discussing how global initiatives and policy changes can promote healthier eating habits at a population level and reduce the burden of heart disease worldwide.

Track 20:  Global Cardiovascular Health and Policies

Cardiovascular diseases are the leading cause of death globally, placing an immense burden on healthcare systems and economies. Global Cardiovascular Health and Policies address the growing global impact of cardiovascular diseases and explore public health strategies aimed at reducing this burden through prevention, early detection, and treatment. Key topics will include the role of governmental and international organizations in shaping public health initiatives that promote healthier lifestyles, regulate tobacco and alcohol consumption, reduce environmental pollution, and improve access to care in underserved regions. Strategies for overcoming these disparities, such as improving access to essential healthcare services, implementing screening programs, and increasing public health education, will be presented. As the global burden of cardiovascular diseases continues to rise, the role of policy interventions, public health campaigns, and international cooperation in reducing this burden will be critical in improving cardiovascular health outcomes worldwide.

Market Analysis

The global heart care market has experienced significant advancements and growth from 2016 to 2025, driven by rising cardiovascular diseases prevalence, evolving healthcare technologies, and increasing awareness about heart health. The International Conference on World Heart Care, scheduled for August 2025 in Toronto, will provide a platform for discussing these ongoing developments and the future outlook for the heart care industry. From 2016 to 2024, the heart care market expanded at a compound annual growth rate of approximately 6.2%. Cardiovascular diseases continue to be the leading cause of death globally, responsible for nearly 32% of all deaths, according to the World Health Organization. This trend has amplified the need for advanced care solutions and has driven both innovation and investment in heart-related medical technologies and treatments. The market was valued at approximately USD 45 billion in 2024 and is expected to reach USD 50.8 billion by 2025.While advancements in heart care are promising, several challenges remain. The high cost of cutting-edge treatments and medical devices, along with stringent regulatory requirements, are key barriers that hinder market expansion. Despite this, the increasing demand for heart disease management offers substantial opportunities for both new and established players in the healthcare sector to invest in innovative solutions. In the pharmaceutical segment, the development of novel drugs for managing cholesterol, blood pressure, and other heart-related conditions has spurred market growth. A notable shift has been the increased use of biologics and personalized medicine, which target the underlying causes of heart diseases more effectively, and advancements in gene therapies that promise revolutionary treatments.
The global heart care market is also benefiting from growing awareness campaigns that promote heart disease prevention, early diagnosis, and the availability of treatment options. Additionally, regions such as North America and Europe, with advanced healthcare infrastructures, are witnessing increased adoption of advanced cardiac therapies. On the other hand, the Asia-Pacific region, with its large and aging population, is experiencing a significant rise in the demand for heart care treatments, contributing to market growth.
By 2025, the market for heart care solutions is expected to be valued at around USD 92.5 billion, with substantial contributions from the pharmaceutical and medical device sectors. Factors such as advancements in digital health technologies, artificial intelligence (AI)-assisted diagnostics, and the growing trend of telemedicine are expected to further revolutionize the landscape of heart care, improving both accessibility and outcomes for patients worldwide. However, the high cost of advanced treatments, regulatory hurdles, and disparities in healthcare access remain key challenges to market growth, particularly in emerging markets where affordability is a concern. Global heart care market is poised for continued growth, with projections indicating it will reach a valuation of USD 92.5 billion by 2025, driven by technological innovations, increasing disease prevalence, and rising healthcare demand across the globe.

Past Conference Report

World Heart 2023

World Heart 2023 regards each one of the individuals to go to the "2nd International Conference on World Heart Care" amidst October 09- 10, 2023 at Zurich, Switzerland which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops, Speaker sessions. 

World Heart 2023 will be an investigation of The Future of Cardiology: “Novel Perspectives on Clinical Cardiology and Heart Diseases” Argument on new technology enhancement in the field of Cardiovascular Disease and current practices in cardiovascular therapy, Cardiac progenitor cells, Hypertension for the primary care clinician, Stent procedure, Balloon Valvuloplasty, Coronary thrombectomy, Noninvasive cardiac imaging, Heart failure, Congestive heart failure, Sports Cardiology and more. Differentiating heart disease and other cardiac conditions constitute a team of healthcare professionals, of which the Cardiology technologist is a key player.

World Heart 2023 will join world-class professors, scientists, researchers, students, Perfusionists, cardiologists to discuss methodology for ailment remediation for heart diseases, Electrocardiography, Heart Failure, Pediatric Cardiology and health disorders.